- Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?
-
Hanouneh I, Alkhouri N, Singal AG
- KMID: 2459787
- Clin Mol Hepatol.
- 2019 Sep;25(3):264-269.
- doi: 10.3350/cmh.2019.1001
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. Prognosis and treatment options largely depend on tumor stage at diagnosis, with curative treatments only available... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-alcoholic fatty liver disease-related hepatocellular carcinoma
-
Daher D, Dahan KSE, Singal AG
- KMID: 2540826
- J Liver Cancer.
- 2023 Mar;23(1):127-142.
- doi: 10.17998/jlc.2022.12.30
Non-alcoholic fatty liver disease (NAFLD), one of the most common causes of liver disease, is an increasingly common cause of hepatocellular carcinoma (HCC). Several demographic, clinical, and genetic factors contribute... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
-
Seif El Dahan K, Daher D, Singal AG
- KMID: 2539802
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S207-S219.
- doi: 10.3350/cmh.2022.0247
Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines... -
- CITED
-
- Close
- SHARE
-
- Close
- Downstaging with atezolizumab-bevacizumab: a case series
-
Kulkarni AV, Kumaraswamy P, Menon B, Sekaran A, Rambhatla A, Iyengar S, Alla M, Venishetty S, Ramachandra SK, Premkumar GV, Sharma M, Rao PN, Reddy DN, Singal AG
- KMID: 2559469
- J Liver Cancer.
- 2024 Sep;24(2):224-233.
- doi: 10.17998/jlc.2024.05.12
Backgrounds/Aims: Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage... -
- CITED
-
- Close
- SHARE
-
- Close
- Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
-
Parikh ND, Zhang P, Singal AG, Derstine B, Krishnamurthy V, Barman P, Waljee AK, Su GL
- KMID: 2411141
- Cancer Res Treat.
- 2018 Apr;50(2):530-537.
- doi: 10.4143/crt.2017.156
PURPOSE: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is often uncertain. We aimed to utilize analytic morphomics, a high-throughput imaging analysis, to assess if body... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
-
Lee YT, Karim MA, Kum HC, Park S, Rich NE, Noureddin M, Singal AG, Yang JD
- KMID: 2541435
- Clin Mol Hepatol.
- 2023 Apr;29(2):453-464.
- doi: 10.3350/cmh.2022.0450
Background/Aims: Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is... -
- CITED
-
- Close
- SHARE
-
- Close
